TY - JOUR
T1 - A robust H8 control approach for blood glucose regulation in type-1 diabetes
AU - Cassany, L.
AU - Gucik-Derigny, D.
AU - Cieslak, J.
AU - Henry, D.
AU - Franco, R.
AU - Ferreira De Loza, A.
AU - Ríos, H.
AU - Olçomendy, L.
AU - Pirog, A.
AU - Bornat, Y.
AU - Renaud, S.
AU - Catargi, B.
N1 - Publisher Copyright:
© 2021 The Authors.
PY - 2021
Y1 - 2021
N2 - The paper addresses the design of a H8 closed-loop dedicated to Blood Glucose (BG) regulation for patients affected by Type-1 Diabetes Mellitus (T1DM). The closed-loop setup is standard, i.e. the H8 feedback controller uses the information provided by a subcutaneous sensor to drive an insulin pump but as opposed to current existing solutions, it is proposed to assess the capabilities of a H8 controller to be designed in a patient-independent way. For that purpose, the design is performed on a family of linear models in order to tackle the variability of a cohort of T1DM patients. Worst-case performance and robust margins are next computed with the help of the H8/µ-analysis theory. The solution is finally assessed on the adult cohort of the high-fidelity UVA/Padova benchmark (v3.2), accepted by the US Food and Drug Administration (FDA) as a substitute for pre-clinical testing of control strategies.
AB - The paper addresses the design of a H8 closed-loop dedicated to Blood Glucose (BG) regulation for patients affected by Type-1 Diabetes Mellitus (T1DM). The closed-loop setup is standard, i.e. the H8 feedback controller uses the information provided by a subcutaneous sensor to drive an insulin pump but as opposed to current existing solutions, it is proposed to assess the capabilities of a H8 controller to be designed in a patient-independent way. For that purpose, the design is performed on a family of linear models in order to tackle the variability of a cohort of T1DM patients. Worst-case performance and robust margins are next computed with the help of the H8/µ-analysis theory. The solution is finally assessed on the adult cohort of the high-fidelity UVA/Padova benchmark (v3.2), accepted by the US Food and Drug Administration (FDA) as a substitute for pre-clinical testing of control strategies.
KW - Blood Glucose Regulation
KW - H8 control
KW - Type 1 Diabetes Mellitus
UR - http://www.scopus.com/inward/record.url?scp=85120709591&partnerID=8YFLogxK
U2 - 10.1016/j.ifacol.2021.10.299
DO - 10.1016/j.ifacol.2021.10.299
M3 - Artículo de la conferencia
AN - SCOPUS:85120709591
SN - 1474-6670
VL - 54
SP - 460
EP - 465
JO - IFAC-PapersOnLine
JF - IFAC-PapersOnLine
IS - 15
T2 - 11th IFAC Symposium on Biological and Medical Systems BMS 2021
Y2 - 19 September 2021 through 22 September 2021
ER -
